A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 Following Single Ascending Dose Administration to Healthy Male Subjects With Elevated LDL-C Levels
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Sep 2019
Price : $35 *
At a glance
- Drugs AZD-8233 (Primary)
- Indications Cardiovascular disorders; Hypercholesterolaemia
- Focus Adverse reactions; Biomarker; First in man
- Sponsors AstraZeneca
- 18 Sep 2019 Planned End Date changed from 6 Dec 2019 to 20 Dec 2019.
- 18 Sep 2019 Planned primary completion date changed from 6 Dec 2019 to 20 Dec 2019.
- 18 Sep 2019 Status changed from recruiting to active, no longer recruiting.